Formulary guidance and transparency from P&T to point of care


Reality Check on Low Testosterone

Market access for low testosterone treatments reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: Under the pharmacy benefit, about 58% of the lives under commercial formularies are covered with utilization management restrictions
  • Class Trends: In February 2020, Clarus Therapeutics, Inc. said that its Jatenzo (testosterone undecanoate) is available by prescription in the U.S. In March 2019, the FDA approved the medication for the treatment of males with low testosterone levels because of specific genetic disorders or pituitary glanddamaging tumors
  • Key Findings: Pharmacy benefit coverage is dominant for products except pellets, which need to be medically implanted. Most policies require trial and failure of generics and injectables before using other dosage forms

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team. Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.